Cost Effectiveness of Screening
A new study shows a “modest mortality” reduction for women of average risk, screened annually by the CA-125. The study tested women annually for the CA-125 blood marker; if those results were abnormal women were referred for a transvaginal ultrasound. The study concluded that a better test than the CA-125 is needed to make this type of screening cost effective.
See the abstract here